Track KROS and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Main
Market Cap$402.82M
Enterprise Value$117.81M
Revenue (TTM)$244.06M
Net Income (TTM)$87.01M
Free Cash Flow (TTM)$105.95M
Financial Health
Cash$287.42M
Net Debt-$285.01M
Debt Ratio0.01
Debt to Equity0.01
Interest Coverage-
Valuation (TTM)
Price to Sales1.65
Price to Earnings4.63
EV to EBITDA1.42
Price to Book1.33
Price to Free Cash Flow3.8
Margins (TTM)
Gross Profit Margin99.52%
EBITDA Margin33.90%
Operating Income Margin28.94%
Net Income Margin35.65%
Free Cash Flow Margin43.41%
Returns (5Y Avg)
Return on Invested Capital-25.39%
Return on Assets-24.13%
Return on Equity-22.40%
Return on Total Capital-25.39%
Return on Capital Employed-25.09%
Dividend Summary
Dividend Yield-
Annual Dividend-
Payout Ratio-
Ex Dividend Date-
5-Year Dividend CAGR-
CAGR (5Y)
Revenue149.98%
Diluted EPS16.05%
Total Debt41.60%
Capital Expenditures39.46%
Free Cash Flow16.43%
CAGR (3Y)
Revenue130.23%
Diluted EPS55.04%
Total Debt74.27%
Capital Expenditures7.72%
Free Cash Flow43.21%
CAGR (1Y)
Revenue1000.00%
Diluted EPS694.30%
Total Debt21.74%
Capital Expenditures-19.68%
Free Cash Flow1000.00%
$10.64+$0.03|+0.28%
52W High$22.55
52W Low$9.69
50D SMA$10.92
200D SMA$14.53
Volume139.64K
Keros Therapeutics Inc
1050 Waltham Street, Lexington, MA, United States, 02421
IPO
2020
Employees
87
Industry
Biotechnology
Sector
Healthcare
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q2 20260+1
1
Q4 20252-2
0
2-quarter cumulative
2 sells1 buys
Analyst Ratings
8 analysts covering
Hold75%recommend hold
Buy
2
Hold
6
Sell
0